Medicare Coverage of Aducanumab — Implications for State Budgets

CMS is considering whether and under what circumstances Medicare will pay for aducanumab for Alzheimer’s disease. A restrictive coverage determination could save the federal government money, but it would also shift substantial costs to states.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-11, Vol.385 (22), p.2019-2021
Hauptverfasser:	Sachs, Rachel E, Bagley, Nicholas
Format:	Artikel
Sprache:	eng
Schlagworte:	Aging Alzheimer Disease Alzheimer Disease - drug therapy Alzheimer's disease and the FDA Antibodies, Monoclonal, Humanized - economics Antibodies, Monoclonal, Humanized - therapeutic use Budget deficits Budgets Centers for Medicare and Medicaid Services, U.S Cost of Health Care Costs Dementia Devices Directors Drug Costs Drug Industry - economics Drugs FDA approval Federal government Geriatrics Health Law Health Policy Humans Insurance Coverage - economics Insurance Coverage - legislation & jurisprudence Medicaid Medicaid - legislation & jurisprudence Medicare Medicare - economics Medicare - legislation & jurisprudence Medicare and Medicaid Monoclonal antibodies Neurodegenerative diseases Neurology Neurosurgery Prescription drugs Reimbursement Mechanisms - economics Reimbursement Mechanisms - legislation & jurisprudence State budgets State Government United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	CMS is considering whether and under what circumstances Medicare will pay for aducanumab for Alzheimer’s disease. A restrictive coverage determination could save the federal government money, but it would also shift substantial costs to states.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMp2115297